A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

NCT03913143 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Leber Congenital Amaurosis 10
Blindness
Leber Congenital Amaurosis
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Eye Diseases
Eye Diseases, Hereditary
Eye Disorders Congenital
Retinal Disease

Interventions

DRUG: sepofarsen
OTHER: Sham

Sponsor

ProQR Therapeutics